Coherus BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Coherus BioSciences, Inc.
The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.
Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.
The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer. Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp